{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:17:26Z","timestamp":1787818646194,"version":"build-2784847793"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07939-7","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:23:14Z","timestamp":1787815394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reconsidering the Association Between GLP-1 Receptor Agonists and Atrial Fibrillation Risk in Chronic Kidney Disease"],"prefix":"10.1007","author":[{"given":"Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"7939_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-026-07897-0","author":"P Dhamelia","year":"2026","unstructured":"Dhamelia P, Khandekar N, Vallurupalli S, et al. GLP-1 agonists and risk of atrial fibrillation in non-dialysis chronic kidney disease. Cardiovasc Drugs Ther. 2026. https:\/\/doi.org\/10.1007\/s10557-026-07897-0.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Supplement_1","key":"7939_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf784.409","volume":"46","author":"K Banerjee","year":"2025","unstructured":"Banerjee K. Effect of glucagon-like peptide-1 receptor agonists on atrial fibrillation incidence: a systematic review and meta-analysis. Eur Heart J. 2025;46(Supplement_1):ehaf784.409. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf784.409.","journal-title":"Eur Heart J"},{"key":"7939_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.910256","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Wang R, Ye H, Wang Y, Wang L, Zhang X. Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:910256. https:\/\/doi.org\/10.3389\/fendo.2022.910256.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"7939_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00970-2","volume":"14","author":"S Wu","year":"2022","unstructured":"Wu S, Lu W, Chen Z, Dai Y, Chen K, Zhang S. Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2022;14(1):195. https:\/\/doi.org\/10.1186\/s13098-022-00970-2.","journal-title":"Diabetol Metab Syndr"},{"key":"7939_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156463","volume":"175","author":"P Karakasis","year":"2026","unstructured":"Karakasis P, Vlachos K, Antoniadis AP, et al. Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism. 2026;175:156463. https:\/\/doi.org\/10.1016\/j.metabol.2025.156463.","journal-title":"Metabolism"},{"issue":"6","key":"7939_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s40256-025-00751-y","volume":"25","author":"S Khalil","year":"2025","unstructured":"Khalil S, Hicks W, Burke FW, Mansi IA. Association of glucagon-like peptide-1 receptor agonist with incident atrial fibrillation. Am J Cardiovasc Drugs. 2025;25(6):803\u201316. https:\/\/doi.org\/10.1007\/s40256-025-00751-y.","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07939-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:23:15Z","timestamp":1787815395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07939-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":6,"alternative-id":["7939"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07939-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This Letter to the Editor provides commentary on a previously published study and does not contain original human or animal research. Therefore, ethics approval and informed consent were not required.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this comment letter, the author used artificial intelligence-assisted tools solely for the purpose of language refinement and grammar checking. No AI tool was used for the generation of scientific content, critical analysis, or the formulation of arguments. The author assumes full responsibility for the intellectual content and accuracy of all statements made herein.","order":3,"name":"Ethics","label":"Statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}